Deciphera Pharmaceuticals (NASDAQ:DCPH) Cut to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a sell rating in a research report sent to investors on Monday morning, Zacks.com reports.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

Other equities analysts have also recently issued research reports about the company. ValuEngine cut Woodward, Inc.Common Stock from a buy rating to a hold rating in a report on Tuesday, April 9th. Piper Jaffray Companies cut Cypress Semiconductor from an overweight rating to a neutral rating in a report on Monday, June 3rd. Finally, BidaskClub cut Weyco Group from a sell rating to a strong sell rating in a report on Saturday, July 13th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock has an average rating of Hold and an average price target of $41.00.

DCPH stock opened at $20.55 on Monday. The business’s 50-day moving average price is $22.85. The company has a market cap of $798.53 million, a PE ratio of -7.29 and a beta of 2.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.55 and a current ratio of 9.55. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $41.00.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Thursday, May 9th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.41). On average, equities analysts expect that Deciphera Pharmaceuticals will post -4.57 earnings per share for the current year.

In other news, CFO Thomas Patrick Kelly sold 1,473 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $25.06, for a total value of $36,913.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 17,250 shares of company stock valued at $403,813 in the last 90 days. 7.02% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in DCPH. Millennium Management LLC grew its holdings in shares of Deciphera Pharmaceuticals by 1,405.1% in the 4th quarter. Millennium Management LLC now owns 1,246,640 shares of the company’s stock valued at $26,167,000 after acquiring an additional 1,163,815 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Deciphera Pharmaceuticals by 73.6% in the 4th quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock valued at $24,625,000 after acquiring an additional 497,427 shares in the last quarter. Orbimed Advisors LLC grew its holdings in shares of Deciphera Pharmaceuticals by 25.0% in the 4th quarter. Orbimed Advisors LLC now owns 2,442,200 shares of the company’s stock valued at $51,262,000 after acquiring an additional 488,700 shares in the last quarter. Norges Bank bought a new position in shares of Deciphera Pharmaceuticals in the 4th quarter valued at about $6,974,000. Finally, Sofinnova Investments Inc. bought a new position in shares of Deciphera Pharmaceuticals in the 4th quarter valued at about $5,572,000. Institutional investors own 58.89% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.